Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 24c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($1.18), $0.24 better than the analyst estimate of ($1.42). Revenue for the quarter came in at $2.96 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• AXT appoints Tracy Liu to its board of directors